Latest From Eyevensys SA
The head of the German family-owned firm's venture fund tells Scrip that investing very early in promising start-ups gives Boehringer Ingelheim "a little bit of a head start" on rival pharma companies in identifying technologies that could translate into therapies five years down the line .
Appointments: Eli Lilly, Cell Medica, Exscientia, Achaogen, Eyevensys, Tessa Therapeutics, EMD Serono, TapImmune, Cue Biopharma
The latest biopharma industry appointments include a key hire for Eli Lilly's oncology R&D team, a new chief executive for Achaogen, an ex-rugby star joining Exscientia and the appointment of a well-known industry figure to the board at Cell Medica.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
- Gene Therapy, Cell Therapy
- Large Molecule
- Medical Devices
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Eyevensys SA
- Senior Management
Patricia Zilliox, PhD, CEO
Francine Behar-Cohen, MD, PhD, CSO
Ronald R Buggage, MD, CMO
- Contact Info
Phone: (0)1 84 79 10 60
11 rue Watt
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.